Unlabelled: The effect of acute beta 1-blockade (100 mg metoprolol) and beta 1/2-blockade (2 mg levobunolol) on exercise performance and metabolism was studied in 16 healthy male physical education students. The study was carried out in a randomized double blind cross-over fashion. The maximal oxygen uptake was unchanged in all conditions, but maximal exercise capacity was reduced by 4% (beta 1-blockade) and 5% (beta 1/2-blockade). Maximal lactate concentration was reduced by 10% (beta 1-blockade) and 20% (beta 1/2-blockade). In 50 min treadmill exercise with 68% of maximal exercise capacity, beta 1/2-blockade led to premature exhaustion in 50% of subjects. Moreover, blood levels of glucose decreased (in some subjects to about 2.5 mmol X 1(-1], while the values were unchanged under beta 1-blockade. Free fatty acids and glycerol were similarly reduced by both beta-blocking agents. HGH, cortisol, adrenalin, and noradrenalin increased under beta-blockade, but more under beta 1/2-blockade than under beta 1-blockade. Insulin remained unchanged as compared with the unmedicated condition. The perceived exertion was elevated under both beta-blocking agents.
Conclusion: Beta 1-blockade affects exercise performance, especially endurance performance, less than beta 1/2-blockade due to unaffected beta 2-receptors mediating glycogenolysis in the skeletal muscles.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Preclinical study of TLR stimulation combined PD-1 antibody enhance the therapeutic effect of microwave ablation on NSCLC.
Clin Transl Oncol
December 2024
Hebei Key Laboratory of Respiratory Critical Care Medicine, The First Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Hebei Institute of Respiratory Diseases, No. 215 Heping West Road, Shijiazhuang, 050000, Hebei, China.
Purpose: The purpose of this study was to investigate the therapeutic efficacy of the combination of microwave ablation (MWA) with immune checkpoints blockade and TLR9 stimulation in the treatment of non-small cell lung cancer (NSCLC) using the C57BL/6 tumor-bearing mice model.
Materials And Methods: Tumor-bearing mice were treated with MWA, programmed cell death protein1 blockade (PD-1) plus MWA (MWA + P), TLR9 agonist CpG ODNs and MWA (MWA + C), PD-1 blockade and CpG ODNs (P + C), MWA plus PD-1 blockade and CpG ODNs (MWA + P + C), or untreated. Survival time was evaluated with the Kaplan-Meyer method comparing survival curves by log-rank test.
N-terminal acetylation of transcription factor LIP induces immune therapy resistance via suppression of PD-L1 expression in non-small cell lung cancer.
J Immunother Cancer
November 2024
Department of Pathology, School of Basic Medical Sciences, Peking University Third Hospital, Peking University Health Science Center, Beijing, China
Article Synopsis
- PD-1 checkpoint blockade has improved cancer treatment, but its effectiveness varies among patients, highlighting the need to understand how PD-L1 expression affects treatment success.
- Researchers used CRISPR/Cas9 screening to identify key regulators of PD-L1 in non-small cell lung cancer (NSCLC), focusing on the transcription factor CEBPB and its isoform LIP, and their impact on PD-L1 transcription.
- The study found that LIP suppresses PD-L1 expression in NSCLC by forming a complex that decreases PD-L1 transcription, suggesting that targeting LIP could improve the effectiveness of immunotherapy.
Liposomal honokiol inhibits non-small cell lung cancer progression and enhances PD-1 blockade via suppressing M2 macrophages polarization.
Phytomedicine
December 2024
Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, Department of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, People's Republic of China. Electronic address:
Background: Honokiol (HNK), a natural phenolic compound derived from Magnolia plants, exhibits therapeutic effects on various diseases, including cancer. The advent of immune checkpoint inhibitors (ICIs) has marked a breakthrough in non-small cell lung cancer (NSCLC) treatment. However, a significant subset of patients exhibits primary or acquired resistance to anti-PD-1/PD-L1 therapies, necessitating the development of novel combination strategies to enhance therapeutic efficacy and overcome resistance.
View Article and Find Full Text PDFCytotoxic T-lymphocyte antigen 4 and programmed cell death ligand 1 blockade increases the effectiveness of interleukin-15 immunotherapy in a bovine leukemia model.
Vet World
September 2024
Laboratory of Immunochemistry and Immunobiotechnology, National Center for Biotechnology, 010000, Astana, Kazakhstan.
Background And Aim: Bovine interleukin 15 (bIL15) is a potential immunotherapy that can block the spread of bovine leukemia virus (BLV). However, immune checkpoints that maintain body homeostasis may reduce their effectiveness. Thus, an analysis of the effectiveness of bIL15 while blocking negative immune regulators is necessary.
View Article and Find Full Text PDFInhibiting triggering receptor expressed on myeloid cells 1 signaling to ameliorate skin fibrosis.
JCI Insight
December 2024
Michigan Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Systemic sclerosis (SSc) is characterized by immune system failure, vascular insult, autoimmunity, and tissue fibrosis. TGF-β is a crucial mediator of persistent myofibroblast activation and aberrant extracellular matrix production in SSc. The factors responsible for this are unknown.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!